Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas.
Forty female patients with pituitary adenomas were studied retrospectively to determine whether factors could be identified that would help predict outcome from operation. Twenty-five patients had a normal prolactin level (less than or equal to 30 ng/ml) during the early postoperative period (less than or equal to 3 months) and 15 patients had persistent disease (prolactin greater than 30 ng/ml). Nine of the 25 patients who initially had normal prolactin levels during the early postoperative period were found to have elevated prolactin levels during the late postoperative period (greater than 3 months). As has been shown previously, tumor size and preoperative prolactin levels were important factors in predicting surgical outcome. Patients with smaller (Hardy Grades I and II) tumors had significantly better outcome than those with larger (Hardy Grades III and IV) tumors. Patients with successful surgical outcomes had significantly lower preoperative prolactin values (204 ng/ml) than those with operative failures (524 ng/ml). In addition to the known factors, the patient's age at the time of operation, the length of amenorrhea, and the patient's growth hormone response to insulin hypoglycemia were newly identified as factors that helped predict surgical outcome. Patients who were less than or equal to 26 years of age and who had had amenorrhea for less than or equal to 6 years at the time of operation had significantly better surgical outcomes. Patients with normal growth hormone responses to stimulation testing had significantly better surgical outcomes than those with a blunted preoperative growth hormone response. The data suggest that prolactin-secreting pituitary tumors may cause a progressive disorder for which operative cure may be obtained only early in the disease.
D000236:Adenoma / Q000150:complications / Q000378:metabolism / Q000601:surgery*; D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000209:etiology; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D010043:Outcome and Process Assessment, Health Care; D010903:Pituitary Gland, Anterior / Q000378:metabolism / Q000601:surgery; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism / Q000601:surgery*; D011379:Prognosis; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012189:Retrospective Studies; D013268:Stimulation, Chemical
D007328:Insulin; D011388:Prolactin; D013006:Growth Hormone